Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- OPTIMA INTEGRATED HEALTH, INC.
- Proposal award date
- 2018-05-01
- Contract end date
- 2019-04-30
- UEI
- ZD6UHHHXNYN8
- Solicitation number
- PA16-302
- Topic code
- NHLBI
Research abstract
HypertensionHTNaffectsmillion Americanswith an annual hospitalization cost of $billion yearClinical trial outcomes of optima BPO BPa clinical reasoning artificial intelligenceAIsystemdetermined
that the success failure of past anti HTN medication treatments can be utilized to improve O BP predictive
performanceOur objective for this Phase I proposal is to investigate the feasibility of building a past treatment
success failurememoryfunction into O BPO BPan innovation of Optima Integrated Healthis functional at
UC San Francisco Medical CenterUCSF MCthe clinical collaborating partnerO BP AI safely optimizes
HTN medication treatment independent of in office visitsIt collects and analyzes current patient health
information from multiple sources to determine if a medication optimization is requiredO BP then alerts the
physician of a need for a medication change by providing a clinically supported treatment recommendation
actionIn this Phase Iwe propose the development and validation of O BPandapos smemoryby using the principles
of Instance Based LearningIBLKnown for its flexibility and intuitive logicthe IBL theory will be adapted to
enhance the predictive treatment efficacy power of O BPIt will lead to incorporating the patient responsesuccess failurefrom past treatments to rank the efficacy of candidate treatments identified by O BP for HTN
medication optimizationClinical resourcese gElectronic Health RecordEHRprovide incomplete patient
informationinsufficient to build thememoryfunctionality using retrospective datasetsThereforein Aima
clinical trialnwill be conducted to collect complete patient datasets that will be used to build thememoryfunctionaBP data from remotely monitored BPbEHR updates to the patientandapos s profile since last
cycle data dumpandcpersonalized online surveys for patient reporting of medication adherencesideeffectsSEsand cardiovascular symptomsAimwill utilize the datasets to develop an efficacy proximity
mapx month of candidate treatments to past treatments using IBL theoryThe proximity map will be based on
scored past treatment sefficacydefined as a combination of success in BP loweringreducing of SEsand
targeting minimum number of drugs with maximum BP lowering powerThe treatment recommendation alert
will be sent to the physicianfor considerationThis study design allows immediate clinical adjudication of the
IBLmemorythrough physicianandapos s choice to implement reject the treatment action alertmade availablex month for each patientMemoryenhanced O BP is expected to lead to a systolic BPSBPreductionmmHg by the end of the scheduledmonths treatment optimization periodSuccessful development and
validation will position thememoryenhanced O BP for deployment at UCSF MC that serves approximatelypatients with an SBP andgtmmHgpoorly controlledand at high risk for primary or recurrent strokeheart failure or myocardial infarctionOur long term objective is to transform the reactive and punctuated
nature of HTN medication treatment management into a proactive and ongoing component of patient care Our goal is to simplify the medication management of high blood pressureBPfor the treating physician while
improving the quality of care of patients and reducing the associated costsWe will develop an artificial
processing intelligence that will allow our current productoptima BPto enhance its efficacy evaluation of
candidate medication treatments as a function of past treatments performanceoptima BP is a decision
support clinical reasoning artificial intelligence designed to safely optimize medication treatment by a physicianindependent of in office visits in patients with poorly controlled BP
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
6 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $7,090,025. Reported amounts are not federal obligations.
Phases: Phase II – Direct to Phase II, Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards